Edition:
United Kingdom

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

25.90USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$25.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
198,077
52-wk High
$26.73
52-wk Low
$7.37

Chart for

About

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides... (more)

Overall

Beta: --
Market Cap(Mil.): $348.59
Shares Outstanding(Mil.): 29.57
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical

* JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING Source text : [http://bit.ly/2mvIp5l] Further company coverage:

11 Jan 2018

BRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES CLOSING OF NUCYNTA COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

10 Jan 2018

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

14 Dec 2017

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

04 Dec 2017

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

04 Dec 2017

BRIEF-Collegium reports third quarter loss of $0.45 per share

* Collegium reports third quarter financial results and provides corporate update

08 Nov 2017

BRIEF-Collegium receives FDA approval for sNDA for Xtampza® ER

* Collegium receives FDA approval for sNDA for Xtampza® ER Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza ER

* Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza® ER

06 Nov 2017

Earnings vs. Estimates